Eli Lilly and Company
LLYHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Eli Lilly and Company (LLY) is listed under Drug Manufacturers - General. With a market capitalization of $1.00T, it sits in mega-cap territory. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Market Cap
$1.00T
Beta
0.50
P/E (TTM)
37.75
P/E (Fwd)
23.78
EPS (TTM)
$29.77
EPS (Fwd)
$47.26
ROE
102.3%
ROA
20.4%
Cash
$8.95B
Total Debt
$54.91B
Free CF
$11.07B
52W Change
52.3%
Annual Financials
Cash vs Debt
Where LLY stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, LLY finished 10.84% above its 150-day moving average ($1059.75) and 11.16% above its 200-day moving average ($1056.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LLY overbought or oversold?
At the August 31, 2026 close, LLY's RSI(14) was 40.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, LLY has $8.95B in cash with $54.91B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $11.07B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 102.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 20.4% further supports the picture of efficient asset utilization. Revenue has grown from $28.54B (2022) to $65.18B (2025), reflecting a 128% increase over the period.
LLY's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Eli Lilly and Company and its sector.